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tatively predict risk of lung cancer incidence.
Methods: Using data and images from the NLST, we
performed post hoc nested case-control analyses. The ﬁrst
analysis was conducted to identify diagnostic quantitative
imaging features that differentiate between malignant
tumors and benign nodules. This study included 88 inci-
dence lung cancer cases diagnosed at the ﬁrst follow-up
interval (T1) and 172 “controls” that had a noduleþ scan
at T1 that was not lung cancer. The second analysis was
conducted to identify predictive quantitative imaging
features that are predictive of lung cancer risk. This study
utilized baseline scans (T0) from 74 subjects who devel-
oped an incidence lung cancer in follow-up intervals and
125 “controls” that had a noduleþ result in follow-up in-
tervals that was not lung cancer. The LDCT scans were
subjected to an in-house “Radiomic Pipeline” that con-
verts images to mineable data (>400 quantitative fea-
tures). Two classes of features were extracted: semantic
and agnostic. Semantic features are commonly used in the
radiology lexicon to describe regions of interest. Agnostic
features are mathematically extracted quantitative de-
scriptors that capture lesion heterogeneity. Separate sta-
tistical analyses were performed for the diagnostic and
predictive features. Univariable analyses and false dis-
covery rate (FDR) were utilized to identify which were
features were statistically signiﬁcant. To generate a
parsimonious model, we performed a backward elimina-
tion process using a 0.1 threshold for inclusion.
Results: Although nodule size has diagnostic utility,
especially among the largest nodules, >80% of cases and
controls had nodules <15 cm. For size alone, we found a
modest AUC of 0.79 when nodules were <15 cm. We
sought to improve the diagnostic capability of size by
adding imaging features. Univariable analyses revealed
that 17 of the features were signiﬁcantly different be-
tween cases and controls. Backward elimination process
revealed a model with 3 imaging features (radius of
smallest enclosing ellipse, radius of largest enclosed el-
lipse, and tumor thickness-pixel) that yielded an AUC of
0.88; and a model with those 3 features, size, and de-
mographics yields an AUC of 0.89. For the risk prediction
analysis, univariable analyses revealed that 10 of the
features were signiﬁcantly associated with lung cancer
risk which remained signiﬁcant when included in a single
model including demographics/risk factors. Backward
elimination process identiﬁed a model with six imaging
features (concavity, border deﬁnition, attachment to
vessel, perinodule emphysema, perinodule ﬁbrosis, nod-
ules in both lungs) and demographics yielding an AUC of
0.87 compared to 0.58 for demographics alone.
Conclusions: These results demonstrate that we can
improve the diagnostic utility of size alone by includingadditional imaging features. Moreover, these data pro-
vide strong and compelling evidence for the utility of
imaging features for risk prediction.Myxomavirus (MYXV) therapy for small
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Introduction: Advanced SCLC is an aggressive neuroen-
docrine subtype of lung cancer that kills approximately
20,000 Americans per year. Despite multiple clinical trials,
there have been few improvements in standard treatments
for the past 3 decades. Therefore, there is a need for new
therapeutic strategies. We have undertaken a multidisci-
plinary project to test the efﬁcacy of an oncolytic MYXV to
preferentially infect, replicate, and kill SCLC cells in human
SCLC primary tumors and derived human andmouse SCLC
cell lines in vitro and in a SCLCGEMMmousemodel in vivo.
Results: We optimized a conditional RB/p130/p53 knock-
out mouse SCLC tumor model (GEMM) using limiting di-
lutions of intra-tracheal Adeno-CRE virus to reduce the
numberofprimary lungSCLC foci inorder to simulatehuman
diseaseand togeneratemouseSCLCcell lines from individual
tumor clones. We tested MYXV in vitro using 14 different
human and mouse SCLC cell lines and observed productive
infection and viral replication associated with cytotoxicity in
tumors cells that grow both adherently and as non-adherent
spheroids. In contrast, we did not detect productive infection
nor cytotoxicity in non-cancerous cells. We analyzed groups
of mice at 1 month interval after adeno-CRE delivery and
determined the optimal time to start intrapulmonary MYXV
delivery when small tumors were present but not yet meta-
static. At 3 days post-treatment, we observed that MYXV
localized to the lungs when tumors were present, but in
control GEMM mice lacking CRE-mediated tumor induction,
MYXV was not detected. Necropsy examination and TUNEL
staining showed apoptosis and necrosis in murine SCLC tu-
mors within 5 days of MYXV treatment, and the effect per-
sistedwith tumornecrosis at 30days post-treatment.We are
currently testing the effect of MYXV delivery on overall sur-
vival in this murine SCLC model system.
Conclusion: MYXV enhances cell killing of human and
murine SCLC cells in vitro and targets SCLC tumors in an
immunocompetent GEMM. Our goal is to study the effect
of MYXV combined with cisplatin cytotoxic chemotherapy
as well as MYXV combined with anti-PD1 and anti-CTLA
February 2016 Abstracts S43immunotherapy in this preclinical GEMM model. We ul-
timately plan to test direct MYXV intralesional injection by
navigational bronchoscopy combined with immuno-
therapy to enhance immune mediated targeting of SCLC.
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Wepreviously demonstrated that proximity ligation assays
(PLA) can be utilized to detect EGFR in complex with its
major signaling adaptor GRB2, which couples the receptor
to the MAP kinase pathway to drive oncogenic prolifera-
tion. These “signaling-associated complexes” correlatewith
EGFR activity, reveal erlotinib pharmacodynamics and are
predictive of improved outcomes to EGFR-directed thera-
pies (Smith et al Science Signaling 2015). Here, we use PLA
to assess cMET signaling, which is being actively investi-
gated in late stage clinical trials in lung cancer and other
solid tumors. We found that the presence of cMET:GRB2
complexes correlates with sensitivity to cMET tyrosine ki-
nase inhibitors (TKI) and the interaction is speciﬁcally
abrogated by MET TKI as measured by biochemical ap-
proaches, cellular viability and PLA. In MET-ampliﬁed
patient-derived xenograft models of lung cancer (N¼6) we
observe MET:GRB2 complexes in regions that also stain
strongly using pMET(Y1234/5) immunohistochemistry
(IHC). Treatment of these models with single agent crizo-
tinib led to variable responses as measured by RECIST
criteria. Ongoing experiments are correlating patterns of
PLA positivity with magnitude of response to MET inhibi-
tion. In clinical cohorts of unselected non-small cell lung
cancer patients (N¼409), MET:GRB2 signaling complexes
are rare (observed in <1%), even among patients whose
tumors are highly positive for cMET protein expression as
detected by IHC. In patients with MET gene ampliﬁcation
veriﬁed by FISH, presence of MET:GRB2 complexes were
observed in 6 of 8 patients with variable intensity and
signiﬁcant spatial heterogeneity. The low rates of
MET:GRB2 signaling complexes observed in patient tissues
may potentially explain the poor response rates observed
in clinical trials targeting cMET in lung cancer. Assays that
candetect therapeutically-relevant protein complexeshave
the potential to improve patient stratiﬁcation strategies
and enable precision medicine in oncology.Natural antisense transcript
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Background: Lung cancer represents an enormous health
burden, representing the most common cause of cancer
death worldwide. The poor therapeutic outcome is largely
due to a complex molecular background as well as late
stage diagnosis, with most patients presenting unresect-
able local tumors, ormetastatic disease.Whilemutations of
driver genes is a well-known mechanism, approximately
half of all non-small cell lung cancer (NSCLC) tumorsharbor
no known clinically relevant oncogenic drivers, empha-
sizing the need to explore alternative mechanisms such as
non-coding RNAs (ncRNAs).
ncRNAs are RNA molecules that do not encode for pro-
tein, but have the ability to regulate DNA, proteins, as well
as other RNA species. These genes exhibit tissue speciﬁc
regulation and have emerged as important players in
several tumor types including lung cancer. Natural anti-
sense transcripts (NATS) are ncRNAs that are transcribed
from the opposite strand of protein coding genes. These
NATs overlapwith, and are often involved in the regulation
of, their sense counterparts. NATs can recruit regulatory
complexes to their transcriptional locus, leading to
silencing of overlapping sense partner gene transcription,
andhave recentlybeendescribed in cancer to silence tumor
suppressor genes such as CDKN2A/B. NATs are quite
prevalent as it is estimated that 25-40% of genes display
overlapping transcriptional partners, emphasizing their
potential in gene regulation. However, only a few NATs
have been characterized in cancer. Here we take an unbi-
ased approach to study NAT deregulation as a mechanism
for altered sense partner expression in NSCLC.
Methods: We performed RNA-sequencing on a set of 65
NSCLC tumors including 36 adenocarcinomas and 29
squamous cell carcinomas as well as
matched nonmalignant lung tissues. A sign-rank test was
used to identify NATs and partner genes with signiﬁ-
cantly altered expression between tumor and matched
normal tissues. These ﬁndings were validated in an
external dataset of lung tumors from TCGA. Survival
analysis was performed using a Cox Proportional hazard
model, as well as the log-rank method.
Results:We have identiﬁed a NAT of OIP5, a lung cancer
oncogene required for chromatin segregation, to be
signiﬁcantly underexpressed in NSCLC. In the same tu-
mors we ﬁnd the overlapping partner gene, OIP5 mRNA,
